Transition Body Lotion

Read the campaign story

Transition Body Lotion is documented by Ogilvy as a Vaseline product developed with transgender women, with Thailand as the market context. The agency describes a two-year research and co-creation process. Its June 2024 LBB case presentation frames the work as a continuing product addition rather than a temporary promotional edition. The campaign year here refers to documented public activity in 2024, not a verified exact launch day.

Editorial interpretation: the distinctive move is to locate the brand statement inside product development. Representation in communication is connected to a practical offer rather than being the entire offer. That raises the standard for execution: an audience should be able to inspect availability, instructions, suitability and support, not merely appreciate a statement of inclusion. The product and the communication need to be assessed together, while respecting their different evidentiary requirements.

The sources contain clinical and inclusion claims, but this educational case does not independently establish product efficacy, medical suitability or changes in wellbeing. It does not offer skincare or treatment advice. D&AD identifies creative and production collaborators; award recognition is not clinical validation. The useful marketing lesson is a disciplined relationship between community input and an actual service or product response, with privacy and professional review wherever health-related information is involved.

Make community input capable of changing the offer

Co-creation should have a decision path, not just a workshop photograph. Before inviting participants, identify which aspects of the proposed offer can change and who has authority to make those changes. Pay contributors fairly and explain what happens when their recommendations conflict with commercial constraints. Keep disagreement visible within the project team instead of selecting only enthusiastic testimonials. A useful record shows which observations led to revisions and which could not be addressed. This makes participation substantive without claiming that a small group speaks for an entire community or that consultation alone guarantees a good outcome.

Separate product evidence from the inclusion story

A persuasive account of an underserved audience does not prove that a product works for them. Technical claims require their own qualified assessment, appropriate testing and careful language. At the same time, a technically sound product can still be difficult to access or unpleasant to buy. Evaluate both dimensions rather than using one to excuse weakness in the other. Marketing teams should know the limits of the evidence they are repeating and avoid converting a participant’s personal experience into a universal promise. For health-adjacent products, a credible brand story must remain narrower than the claims professionals can substantiate.

Design access without requiring public disclosure

People should not have to explain personal circumstances publicly to obtain an ordinary product or service. Review shelf placement, ordering, packaging and customer support from that perspective. Public storytelling must be separately optional and should not become the price of participating in research. Use the minimum personal information necessary, give participants control over attribution and avoid collecting medical histories for a marketing exercise. Long-term availability also matters: a highly visible launch that disappears quickly can undermine the practical promise. Plan how the offer will be supported after the campaign’s most photogenic moment has passed.

A bounded test for another brief

Proposed adaptation: an accessories brand could invite a paid, diverse group of adults to help redesign an everyday carry pouch. Focus on practical preferences such as fastening, organisation and discreet packaging, without collecting health information or asking participants to disclose identity details publicly. Compare the revised prototype with the existing version through voluntary usability sessions. Explain which changes came from participants and obtain separate permission for any attributed story. Keep the product test distinct from publicity and offer a private feedback route. This tests whether community input improves an ordinary nonmedical product while avoiding clinical claims or an imitation of the original lotion.

Measure task completion, comfort with the research process, specific requested revisions and willingness to use the prototype. Record unmet needs and disagreement. Do not turn preference feedback into evidence of health benefits, social acceptance or universal representation.

Stop if participation requires unwanted disclosure, the offer cannot be maintained or communication makes medical claims beyond independently appropriate evidence.